Bicycle Therapeutics could net over $400m in haemophilia deal

« Back to Industry News

08/09/2017

Bicycle Therapeutics has teamed up with another biotech firm in a bid to tackle haemophilia and sickle cell disease in a deal which could net it over $400m.

It has launched a research collaboration with Bioverativ, a life sciences firm focused on treating haemophilia and other rare blood disorders, which will look for new treatments for the conditions.

The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body.

Bicycle Therapeutics will be responsible for leading initial discovery activities through lead optimisation to candidate selection for two programs, and will receive a $10m upfront payment and near-term research and development funding of $4.2m. Bicycle is eligible to receive up to $410m related to development, regulatory and commercialisation milestones for products planned under the two programs, as well as undisclosed royalty payments.

“We believe our Bicycle platform has extremely broad therapeutic potential and we are excited to work with Bioverativ, a standout leader in the haematology field, to explore Bicycles in this important area of clinical need,” said Kevin Lee, Chief Executive Officer of Bicycle Therapeutics.

“Combining Bioverativ’s deep expertise in haematology with our powerful platform offers great promise for the development of novel, targeted therapies for patients. This alliance provides the latest validation of our Bicycle platform and furthers our strategy to evaluate its potential in a wide range of new disease areas.”

Dr Tim Harris, executive vice president of R&D at Massachusetts-based Bioverativ, added: "We are constantly exploring new ways to do innovative science to find new molecules that can advance the care of people living with rare blood disorders.

“This collaboration offers a unique opportunity to identify an entirely new therapeutic modality that may lead to meaningful new treatments and outcomes for people living with haemophilia and sickle cell disease. We are delighted to be working with Bicycle to pursue our shared goal of creating progress for patients with great unmet treatment needs.”


Click here to view the related article.

« Back to Industry News